Final Program
h6okmgq
h6okmgq
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
68 SUNDAY • MAY 15<br />
P616<br />
P617<br />
P618<br />
Clinical Features and Associated Likelihood of Primary Ciliary<br />
Dyskinesia in Adults /K.M. Sullivan, M.L.A. Daniels, J.J.<br />
Atkinson, T.W. Ferkol, D. Hall, H.-S. Lee, H. Metjian, K.N. Olivier,<br />
M. Rosenfeld, C.E. Milla, M. Zariwala, S.D. Sagel, J. Carson, J.<br />
Krischer, M. Hazucha, M. Knowles, M. Leigh, Genetics Disorders<br />
Of Mucociliary Clearan, p.A1765<br />
Determinants of Respiratory Function in Adults Patients with<br />
Primary Ciliary Dyskinesia/J. Frija-Masson, L. Bassinet, I.<br />
Honore, N. Dufeu, B. Housset, A. Coste, J.-F. Papon, E. Escudier,<br />
P.-R. Burgel, B. Maitre, Creteil, France, p.A1766<br />
Maximal Mid-Expiratory Flow Is a Surrogate Marker of Lung<br />
Clearance Index for Assessment of Adults with<br />
Bronchiectasis/W.-J. Guan, J.-J. Yuan, Y.-H. Gao, H.-M. Li, J.-P.<br />
Zheng, R. Chen, N. Zhong, Guangzhou, China, p.A1767<br />
P619 Baseline Demographic Profile of Subjects of the Phase 3<br />
RESPIRE 2 Trial of Ciprofloxacin Dry Powder for Inhalation<br />
(DPI) in Non-Cystic Fibrosis Bronchiectasis (NCFB)/T.R.<br />
Aksamit, A. De Soyza, E. Operschall, T.-J. Bandel, U. Krahn, E.<br />
Montegriffo, M. Criollo, R.C. Wilson, Rochester, MN, p.A1768<br />
P620<br />
P621<br />
Facilitator:<br />
P622<br />
P623<br />
P624<br />
P625<br />
P626<br />
Prevalence of Airflow Limitation in Patients with<br />
Bronchiectasis, and Its Effect on Acute Exacerbation and the<br />
Decline of Lung Function/J.-M. Kim, S.M. Choi, J. Lee, Y.S. Park,<br />
C.-H. Lee, S.-M. Lee, J.-J. Yim, Y.W. Kim, S.K. Han, C.-G. Yoo,<br />
Seoul, Korea, Republic of, p.A1769<br />
Relationship Between Airway Inflammatory Biomarkers and<br />
Functional Status in Non-Cystic Fibrosis Bronchiectasis/M.A.<br />
Roggi, F.L. Dente, M. Latorre, M. Bilotta, D. Nieri, M.L. Bartoli, S.<br />
Cianchetti, B. Vagaggini, P. Paggiaro, Pisa, Italy, p.A1770<br />
N.M. Quesada, MD, Chicago, IL<br />
Acute Exacerbations of Non-Cystic Fibrosis Bronchiectasis:<br />
What Can Promise Non-Invasive Ventilation for Patients with<br />
Type 2 Respiratory Failure?/A. Sadigov, S. Akhundov, F.<br />
Abdullayev, Baku, Azerbaijan, p.A1771<br />
Pseudomonas Colonization, Lung Function, Computed<br />
Tomography, and Macrolides in Non-Cystic Fibrosis<br />
Bronchiectasis: What Can We Wait from These Dates?/A.<br />
Sadigov, G. Sadigova, S. Huseynova, I. Ashirova, Baku,<br />
Azerbaijan, p.A1772<br />
The Relationship Between Vitamin D Levels and Lung<br />
Function, Clinical Indices, Depression and Anxiety Symptoms<br />
in Adult Patients with Non-Cystic Fibrosis Bronchiectasis/M.<br />
Bekir, D. Kocakaya, S. Olgun Yildizeli, H. Arikan, E. Eryuksel, B.<br />
Bagci Ceyhan, Istanbul, Turkey, p.A1773<br />
Non-Cystic Fibrosis Bronchiectasis in Patients with<br />
Hematologic Malignancy/L.W. Chen, W.B. Karkowsky, S.<br />
Montner, P.J. McShane, S.R. White, M.E. Strek, Chicago, IL,<br />
p.A1774<br />
ORBIT-3 and ORBIT-4: Design of a Phase 3 <strong>Program</strong> to<br />
Investigate Safety and Efficacy of Pulmaquinr in Non-Cystic<br />
Fibrosis Bronchiectasis (NCFBE) Patients Chronically<br />
Colonized with Pseudomonas Aeruginosa (PA)/A. O’Donnell, D.<br />
Bilton, D. Serisier, A. Wanner, J. Froehlich, P. Bruinenberg, I.<br />
Gonda, Washington, DC, p.A1775<br />
P627<br />
P628<br />
P629<br />
P630<br />
P631<br />
P632<br />
P633<br />
Facilitator:<br />
P634<br />
P635<br />
P636<br />
P637<br />
P638<br />
P639<br />
P640<br />
Profile of Exacerbations Among Patients with Non-Cystic<br />
Fibrosis Bronchiectasis at the State University of Rio de<br />
Janeiro/R.K.R. Leal, R.E.B. Salles, W. Costa, A.B.A. Silva, T.F.<br />
Cruz, B.R.A. Silva, Rio de Janeiro, Brazil, p.A1776<br />
Respiratory Failure After Bronchial Arterial Embolization in<br />
Patients with Cystic Fibrosis: An Institutional Review/J.A.<br />
Town, M.L. Aitken, Seattle, WA, p.A1777<br />
Procalcitonin Levels in Cystic Fibrosis Exacerbations/G. Loh,<br />
A. Skabelund, A. French, J. Morgan, San Antonio, TX, p.A1778<br />
Perfluorinated Gas MRI to Detect Regional Ventilation<br />
Heterogeneity in Cystic Fibrosis/J.L. Goralski, E.O. Akinnagbe,<br />
C. Salazar, R.C. Boucher, Y.Z. Lee, S. Donaldson, Chapel Hill, NC,<br />
p.A1779<br />
Use of Ultra-Low Dose Chest Computed Tomography<br />
Scanning to Detect Emphysema in Patients with Cystic<br />
Fibrosis/G. Dalgleish, H. Sahi, K. Lau, C. Daley, D. Garner, P.<br />
King, Clayton, Australia, p.A1780<br />
Atlas-Based Analysis of MRI Measures of Lung Water Density<br />
to Identify Regional Lung Abnormalities in CF Adults/<br />
R.J. Theilmann, A.R. Elliott, C. Darquenne, D.J. Conrad, La Jolla,<br />
CA, p.A1781<br />
The Impact of Aspergillus Fumigatus and Its Treatment on<br />
Outcomes in Cystic Fibrosis/T. Basnayake, F. Finlayson, A.<br />
Peleg, J. Wilson, T. Kotsimbos, Prahran, Australia, p.A1782<br />
E.T. Naureckas, MD, Chicago, IL<br />
The Genetic Profile of Chinese Patients with Cystic Fibrosis/X.<br />
Tian, Y. Liu, X. Li, X. Zhang, K.-F. Xu, Beijing, China, p.A1783<br />
Fenretinide Normalizes Aberrant Lipid Metabolism and<br />
Prevents Excessive Inflammation During Pulmonary<br />
Exacerbation in Adult Cystic Fibrosis Patients/D. Radzioch, G.<br />
Wojewodka, S. Cupri, P. Colin, R. Pislariu, D. Garic, I. Kianicka, E.<br />
Matouk, Montreal, Canada, p.A1784<br />
How does CPET Compared to Yearly Lung Function Follow-Up<br />
in Adult Cystic Fibrosis Patients/T.S. Hynes, P. Harnett, B.<br />
Casserly, Limerick, Ireland, p.A1785<br />
Severity Index in Pulmonary Exacerbations in Cystic<br />
Fibrosis/L. Diab, R.M. Giron, E. Garcia, C. Marcos, M. Hernandez,<br />
J.L. Justicia, C. Acosta, J. Ancochea, Madrid, Spain, p.A1786<br />
Nebulizer Aerosol Performance and Patient Acceptance in<br />
Cystic Fibrosis/C. Landon, G. Garza, Ventura, CA, p.A1787<br />
Study Design: Effects of Long Term TobrAmycin Inhalation<br />
Solution (TIS) Once Daily on Exacerbation Rate in Patients<br />
with Non-Cystic Fibrosis Bronchiectasis. A Double Blind,<br />
Randomized, Placebo and TIS Twice Daily (open label)<br />
Controlled Trial. The BATTLE/L. Terpstra, J. Altenburg, R.<br />
Duijkers, W.G. Boersma, Alkmaar, Netherlands, p.A1788<br />
Epidemiology And Natural History of Pseudomonas<br />
aeruginosa Infection in Patients with Non-Cystic Fibrosis<br />
Related Bronchiectasis/R. Lim, T. Woo, J. Duong, B. Waddell, C.<br />
Mody, H. Rabin, D.G. Storey, M.D. Parkins, Calgary, Canada,<br />
p.A1789<br />
ATS 2016 • San Francisco